• View Cart
  • FAQs
  • LOG IN
Biotech Primer WEEKLY
  • Home
  • Training Options
    • Customized Onsite Training
    • Live, Online 1 & 2-Day Master Courses
    • On-Demand, Online 60-Minute Classes
    • Master Course Recordings
    • Corporate Learning
  • About Us
    • Our Expertise
    • Our Experience
    • Our Clients
    • Contact Us
  • Our Publications
    • The WEEKLY Newsletter
    • 2020 WEEKLY Compendium
    • 2015-2020 Quinquennial
      Compendium
    • Biotech Primer Book
    • Biotech for Non-Scientists Course SnapShot
    • Online Course Snapshot
    • Medical Device Course Snapshot
    • Drug Development Course SnapShot
    • Manufacturing Course SnapShot
Select Page
Potential Of PCSK9 Inhibitors

Potential Of PCSK9 Inhibitors

by Emily Burke, PhD | Jun 25, 2015 | Metabolic & Cardiovascular Disease

$23 Billion Blockbuster? The PCSK9 inhibitor buzz keeps rolling, especially since sitting before the FDA Advisory Committee earlier this month.  Amgen’s (Thousand Oaks, CA) Repatha and Sanofi’s (Paris, France) Praluent are a new class of cholesterol lowing...

About Biotech Primer

From startups to the Fortune 500, we train employees at companies of all sizes. We offer customized, in-house courses and open enrollment classes. Visit Biotech Primer for more information.

In a hurry? Take our online classes today.

Subscribe to The WEEKLY

Contact Us | Privacy Policy | Biotech Primer © 2021